| CARVIEW |
Generate novel, synthesizable compounds tailored to your Target Product Profile
Enki™ rapidly generates selective, drug-like compounds—cutting timelines and unlocking faster discovery cycles.
Stop screening and start generating with Enki™, our fully-trained generative AI foundation model, which provides R&D teams with target-specific compounds beyond the bounds of existing libraries.
Redefining the unit economics of drug discovery for better patient outcomes
With an estimated 10⁶⁰ possible drug-like molecules, the chemical space is unimaginably large. And yet, drug discovery has only scratched its surface.
At Variational AI, we believe that the future of drug discovery lies not in screening molecules but in generating them. Using generative AI, we create novel, synthesizable small molecules optimized across multiple objectives such as potency, selectivity, and safety, without relying on massive screening libraries.
Our platform, Enki™, enables rapid exploration of uncharted chemical space — transforming the cost, speed, and scope of small molecule drug discovery, starting with oncology.
A simple workflow made to fit with your discovery process
From target product profile to synthesis-ready leads in weeks. Enki™ generates and optimizes novel compounds to meet selectivity, potency, toxicity, and pharmacokinetic goals.
1. Define the preclinical target product profile (TPP)
Specify the On/Off-targets and physico-chemical properties of the molecules as input for Enki™ generative AI.
2. Enki™ generates compounds
Enki™ generates novel and diverse structures that meet the defined TPP.
3. Make your selection
Pick compounds you want to synthesize and test. Enki™ can also perform hyper-efficient lead optimization while constrained to a defined scaffold.
Designed for early discovery
Purpose-built for early discovery, Enki™ helps generate first- and best-in-class compounds across multiple therapeutic areas
Generative AI, not screening
We generate new molecules de novo — freeing you from reliance on experimental or virtual libraries.
Multi-objective optimization
Enki™ simultaneously optimizes for more than 50 physico-chemical properties reflecting potency, selectivity, toxicity, PK, synthesizability and ADME.
Transforming drug discovery with AI
At Variational AI, we bring together machine learning researchers, chemists, and biotech professionals united by one mission: transforming early drug discovery with generative AI. Our cross-disciplinary team is always looking for new talents to push the boundaries of science and technology alongside us.
Latest News
Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Building on their initial hit series, Variational AI and Rakovina Therapeutics share promising new results…
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, Inc., a generative AI drug discovery company, announced a collaboration with Merck, known…
Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Following their successful 2022 collaboration, which targeted the SARS-CoV-2 main protease, Variational AI and Life…
Variational AI Joins Agora Open Science Trust to Advance PRMT6 Inhibitors for SBMA
Variational AI is proud to announce its participation in a new open science drug discovery…
Stay updated with all news & events
Our next event is…
Variational AI at JPM Week and Biotech Showcase 2026
Each January, the J.P. Morgan Healthcare Conference turns San Francisco into the global epicenter of biotech, pharma, and healthcare investing.…
Event Dates
12–15 January, 2026
Location
San Francisco, CA
See all events
